Annual Report 2009 Active Biotech AB (publ)
(Thomson Reuters ONE) -
Active Biotech's Annual Report 2009 is now available for download at
www.activebiotech.com
The Annual Report will only be digitally distributed.
Lund, April 20, 2010
Active Biotech AB (publ)
Tomas Leanderson
President & CEO
For further information, please contact:
Göran Forsberg
Vice President Investor Relations & Business Development
Tel +46 (0)46 19 11 54
Active Biotech AB (OMX NORDIC: ACTI), headquartered in Sweden, is a
biotechnology company with R&D focus on autoimmune/inflammatory diseases and
cancer. Projects in pivotal phase are laquinimod, an orally administered small
molecule with unique immunomodulatory properties for the treatment of multiple
sclerosis, as well as ANYARA for use in cancer targeted therapy, primarily renal
cancer. Further key projects in clinical development comprise the three orally
administered compounds TASQ for prostate cancer, 57-57 for SLE and RhuDex(TM)
for RA. Please visit www.activebiotech.com for more information.
Active Biotech AB (Corp. Reg. No. 556223-9227)
Box 724, SE-220 07 Lund
Tel: +46 46 19 20 00
Fax: +46 46 19 11 00
Active Biotech is obligated to publish the information contained in this press
release in accordance with the Swedish Securities Market Act. This information
was provided to the media for publication on April 20, 2010, at 10:00
a.m.
[HUG#1405573]
Unternehmensinformation / Kurzprofil:
Datum: 20.04.2010 - 10:05 Uhr
Sprache: Deutsch
News-ID 19318
Anzahl Zeichen: 0
contact information:
Town:
LUND
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 403 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Annual Report 2009 Active Biotech AB (publ)"
steht unter der journalistisch-redaktionellen Verantwortung von
Active Biotech (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
